Postoperative EGFR-TKI Therapy forContralateral Pulmonary Nodules in Patients With EGFR-Mutant NSCLC（ARMOR2501）

"A total of 32 patients with bilateral operable sMPLC will be prospectively enrolled. After unilateral tumor resection and confirmation of EGFR mutation positivity, they will be included in the study.~Before formal enrollment, participants must be completely free from perioperative complications or have recovered from any complications. Enrolled patients will undergo baseline follow-up within 4 to 10 weeks postoperatively and start a three-month EGFR-TKI treatment on the same day. Patients will receive a CT follow-up at the end of the three-month treatment period. If they experience intolerable treatment-related adverse effects, EGFR-TKI treatment will be discontinued.~If the lesion persists after three months, a multidisciplinary team will determine whether to proceed with surgical treatment."